Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392154 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,153
- Enrollment target
NCT04392154: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT04392154 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,153 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04392154, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,153 participants
- Enrollment target
Study Summary
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Primary Outcome
Percentage of participants discontinued from study treatment due to adverse events is reported.
Interventions
- BIOLOGICAL Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,153 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2025-04-22 |
| Phase | Phase 3 |
What the finished NCT04392154 record still lists
NCT04392154 is an interventional study that assigns participants to a tested intervention. Its 1,153 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% higher).
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT04392154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04392154 about?
NCT04392154 is a clinical study titled "Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)". This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
What is the current status of trial NCT04392154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,153 participants. The study started on 2020-06-15. Estimated completion is 2025-04-22.
What interventions are being tested in trial NCT04392154?
The interventions under investigation include: Lebrikizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04392154?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04392154's enrollment target sits among peer trials
1,153 238th of 2000 higher than 1,763 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI